Centanafadine is one of 116 small molecule programs targeting Attention Deficit Hyperactivity Disorder. It is currently in Phase 3.
Indications
Total Trials
Active Trials
Competitors
Pipeline
Competition
139 competitors in Trial
Opdivo
Yervoy
Eloxatin
Camptosar
Perjeta
Vectibix
Platinol
Tarceva
Herceptin
Adrucil
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Clinical
Sources